LexBlog IP

DECEMBER 13, 2023

Samsung Bioepis recently reported that it has signed a settlement and license agreement with Johnson & Johnson (“J&J”) in the United States relating to SB17, Samsung Bioepis’s ustekinumab biosimilar to J&J’s STELARA® If SB17 is approved by the FDA, the license period in the United States will begin on February (..)

Litigation 52

Litigation Settlement Licensing Marketing 52

The IPKat

AUGUST 31, 2023

Open-Source: Requiring code to be openly available may promote transparency and innovation; allowing it to be proprietary may concentrate market power but allow more dependable regulation of harms. Existential: Some people think that AI is a major threat to human life. You can read the full report here.

Reporting 89

Reporting Technology Intellectual Property Government 89

LexBlog IP

JUNE 13, 2023

. “According to the settlement agreement, AVT04 (ustekinumab) can be marketed in the US, subject to regulatory approval, no later than February 21, 2025.” The post Alvotech and Teva Reach Ustekinumab (STELARA) Settlement with J&J appeared first on Big Molecule Watch.

Settlement 52

Settlement Marketing Marketing Licensing 52

LexBlog IP

AUGUST 16, 2023

On August 7, 2023, Formycon AG and Fresenius Kabi announced that they have reached a settlement with Johnson & Johnson (“J&J”) in the United States relating to FYB202, a proposed ustekinumab biosimilar to STELARA®, marketed by J&J. Economic terms of the settlement were not disclosed in the press release.

Settlement 52

Settlement Licensing Confidentiality Marketing 52

LexBlog IP

AUGUST 30, 2023

market on March 7, 2025, if approved by FDA. It has been reported that Celltrion has finalized a settlement with Johnson & Johnson (“J&J”) in the United States relating to CT-P43, Celltrion’s ustekinumab biosimilar to J&J’s STELARA®, which would permit Celltrion to launch the product in the U.S.

Settlement 52

Settlement Confidentiality Marketing Marketing 52

LexBlog IP

FEBRUARY 23, 2024

The settlements cover Canada, the European Economic Area, and Japan, clearing the way for Alvotech to launch AVT04 in those markets, where AVT04 has already received regulatory approval. Alvotech has commercial partners for AVT04 in each of the aforementioned markets. Per the settlement agreement, AVT04 can be marketed in the U.S.,

Settlement 52

Settlement Marketing Marketing Licensing 52

IIPRD

MARCH 17, 2023

Subsequently, the healthcare sector has gained precedence and command over the market. The global nutraceutical market (including functional food, functional beverages, and dietary supplements) is anticipated to grow by 7.5% (CAGR) between 2022 and 2027, in which the United State market share is considered to be the biggest.

IP 52

IP Intellectual Property Marketing Marketing 52

Technology & Marketing Law Blog

FEBRUARY 29, 2024

Earlier this month, the High Tech Law Institute hosted the 2024 Works-in-Progress Intellectual Property ( WIPIP ), featuring nearly 90 presentations and over 110 attendees from four continents. WIPIP 2025 will be hosted by the UNLV Law School in Las Vegas. * * * As usual, Prof. The photo album. My memoriam for Dan.

Fair Use 69

Fair Use Intellectual Property IP Law 69

LexBlog IP

JANUARY 16, 2023

The European Commission expressed its hope that the provisions of the regulation will enter into force across all EU member states in 2025. These include, among others, the use to take decisions that may be detrimental to a natural person or the use for advertising or marketing.

Intellectual Property 52

Intellectual Property Confidentiality Business Advertising 52

LexBlog IP

JANUARY 12, 2023

Coherus plans to file an abbreviated Biologics License Application (aBLA) with the FDA later this year and intends to launch the product at EYLEA biosimilar market formation, currently expected to be in 2025.

Marketing 52

Marketing Marketing Licensing Intellectual Property 52

LexBlog IP

SEPTEMBER 28, 2023

to commercialize several of Abbott’s oncology, women’s health, and respiratory disease biosimilars for emerging markets in Latin America, Southeast Asia, the Middle East, and Africa. According to the press release, the first molecules subject to the agreement are expected to launch as early as 2025.

Marketing 52

Marketing Marketing Contracts Registration 52

The IPKat

NOVEMBER 9, 2023

Big) Kat in Tbilisi The Validation Agreement promises to bolster the protection of intellectual property rights within the industrial sector, thus safeguarding and promoting innovation and technological progress in the country. As of now, there are two traditional routes to obtain patent protection for an invention in Georgia.

Intellectual Property 67

Intellectual Property Patent Application Patent IP 67

IP Tech Blog

OCTOBER 31, 2023

Based on Ofcom guidance issued yesterday ( [link] ) it appears that the service provider categorisation process will not be completed until the end of next year at the earliest with draft proposals regarding the additional requirements for these larger providers to follow in early 2025.

Law 62

Law Social Media Publishing Technology 62

LexBlog IP

OCTOBER 31, 2023

Based on Ofcom guidance issued yesterday ( [link] ) it appears that the service provider categorisation process will not be completed until the end of next year at the earliest with draft proposals regarding the additional requirements for these larger providers to follow in early 2025.

Law 52

Law Social Media Publishing Intellectual Property 52

LexBlog IP

NOVEMBER 5, 2023

The licensure and marketing of WEZLANA could affect negotiations with CMS regarding Medicare pricing for STELARA under the Inflation Reduction Act’s Drug Price Negotiation Program. According to a reported statement from Amgen, its settlement agreement with Janssen allows Amgen to sell WEZLANA “no later than January 1, 2025.”

Marketing 40

Marketing Marketing Government Litigation 40

Biswajit Sarkar Copyright Blog

DECEMBER 19, 2023

As India aims for a $5 trillion economy, the MSME ministry sets ambitious goals, aiming to elevate their GDP contribution by up to 50% by 2025. MSMEs foster innovation by nurturing aspiring entrepreneurs, encouraging the development of innovative goods that enhance market competitiveness and fuel sustained growth.

Settlement 52

Settlement Intellectual Property Registration Designs 52

LexBlog IP

FEBRUARY 1, 2024

In October 2023, Accord settled with Janssen Biotech under confidential terms that would allow Accord to launch its proposed ustekinumab biosimilar no later than May 15, 2025, pending FDA approval.

Confidentiality 52

Confidentiality Reporting Licensing Marketing 52

LexBlog IP

DECEMBER 2, 2021

The incorporation of drones in logistics, security, exploration, agriculture, and transport has led to a projected growth of the drone market to $129.2 billion by 2025.

Privacy 40

Privacy Marketing Marketing Law 40

LexBlog IP

JANUARY 11, 2022

Subscription marketing is on the rise with some predicting the subscription industry will more than double by 2025. Experts do not forecast this growth will taper off, as it is part of a larger trend of relationship-based marketing. Or perhaps the goal was really to drive app download and loyalty signups.

Marketing 52

Marketing Marketing Contracts Law 52

LexBlog IP

AUGUST 12, 2021

1, 2025, to Dec. 31, 2025, and requires 15% PCR by weight. The Guides for the Use of Environmental Marketing Claims (Green Guides) are set to be reviewed and revamped in 2022. The Green Guides help marketers ensure their environmental claims are not unfair or deceptive. 1, 2022, to Dec. And by Jan. 1, 2023, through Dec.

Marketing 52

Marketing Marketing Business Advertising 52

LexBlog IP

JANUARY 25, 2024

The licensure and marketing of WEZLANA could affect negotiations with CMS regarding Medicare pricing for STELARA under the Inflation Reduction Act’s Drug Price Negotiation Program. According to a reported statement from Amgen, its settlement agreement with Janssen allows Amgen to sell WEZLANA “no later than January 1, 2025.”

Marketing 52

Marketing Marketing Licensing Litigation 52

LexBlog IP

JUNE 29, 2023

To demonstrate irreparable harm, Biogen pointed to harm in the form of (1) price erosion, (2) lost sales and market share, and (3) reputational harm. For similar reasons, the Court found Biogen’s arguments about loss of market share too speculative. The Court also noted that any harm could be remedied by money damages.

Litigation 52

Litigation Marketing Marketing Patent 52

LexBlog IP

JANUARY 17, 2024

Any reporting company that is created or registered before January 1, 2024, must file a BOI report no later than January 1, 2025. The CTA takes effect on January 1, 2024.

Reporting 52

Reporting Business Editing Ownership 52

LexBlog IP

AUGUST 29, 2023

Any reporting company that is created or registered before January 1, 2024, must file a report no later than January 1, 2025. Reports will not be accepted prior to January 1, 2024. FinCEN is currently in the process of creating the specific reporting system and additional regulations surrounding the CTA.

Reporting 52

Reporting Ownership Business Editing 52

Kluwer Copyright Blog

DECEMBER 13, 2023

In this post, the focus is on the unlicensed use of copyright-protected works in the context of training GenAI models, where such use could jeopardise the market for those particular expressions (see Sobel ). .’ Setting the Scene Much ink has been spilled on the legal discourse surrounding generative AI (GenAI) and copyright.

Copyright 52

Copyright IP Music Licensing 52

LexBlog IP

AUGUST 14, 2023

Reporting Companies created before January 1, 2024, have one year (until January 1, 2025) to file the required information. -sourced revenue, and a physical operating presence in the U.S.; Reporting Companies created on or registered prior to January 1, 2024, are not required to report their Company Applicant. When do I Need to Report By?

Business 52

Business Ownership Reporting Registration 52

SpicyIP

OCTOBER 31, 2023

She is keenly interested in Intellectual Property Law, Technology Law, and Corporate Law ]. – In 2020, a total of 2,38,908 women were affected as per the National Cancer Registry Program Report , and this is projected to rise by 2025 to become the most common site for cancer in women. Tejaswini is a 3rd-year B.A.

Licensing 72

Licensing Government Reporting Patent 72

Fish & Richardson Trademark & Copyright Thoughts

DECEMBER 2, 2020

billion by 2025. [ii] As with any growing industry, cannabis stakeholders are eager to protect their valuable intellectual property (IP) rights, but their ability to obtain comprehensive IP protection and enforce their IP rights is sometimes in conflict with federal drug law. billion, with an expected increase to $29.7

IP 52

IP Registration Trademark Branding 52

The IPKat

FEBRUARY 29, 2024

Role of EUIPO The role of European Union Intellectual Property Office (EUIPO) in examining the GI applications was one of the most contentious points in the negotiations over the GI Regulation. It will be applicable as of 1 January 2025. Examination at the EU-wide level will be conducted by the European Commission.

Art 109

Art Registration Journalism Intellectual Property 109

Fish & Richardson Trademark & Copyright Thoughts

FEBRUARY 4, 2021

At the same time, market uptake of biosimilars in the United States continued to increase, suggesting that there is room for expansion of biosimilars in the U.S. In addition, fewer new biosimilars entered the market this past year, with five biosimilar launches in 2020 as compared to seven in 2019. Yet biosimilars of anti-TNF?

Litigation 52

Litigation Settlement Marketing Marketing 52

LexBlog IP

APRIL 25, 2023

” Government should announce a clear policy position on the relationship between intellectual property law and generative AI to provide confidence to innovators and investors. labelling) on generated output to support right holders of copyrighted work. and] will explore how this could be expanded.

Technology 52

Technology Government Reporting Intellectual Property 52

LexBlog IP

DECEMBER 28, 2023

Ltd. (“THDB”) to market three biosimilars of the top selling branded insulins in the United States – asprat, lispro and glargine. Coherus intends to launch the product at EYLEA biosimilar market formation, currently expected to be in 2025, if approved. All are expected to begin clinical trials in 2024.

Licensing 52

Licensing Reporting Marketing Marketing 52

LexBlog IP

DECEMBER 31, 2022

In the intellectual property (IP) space, there has been explosive growth in this area, with AI-based patent filings addressing trending areas, including disease identification and diagnosis, drug discovery, personalized medicine, and clinical trials, among others. Disease Identification and Diagnosis. population.

Intellectual Property 52

Intellectual Property IP Technology Privacy 52

LexBlog IP

AUGUST 25, 2023

In effect, the Maximum Fair Price (MFP) must be set at no more than 40-75% (depending on how long the product has been on the market without generic or biosimilar competition) of what the drug’s average manufacturer price was in the year 2021. Beginning in 2025, CMS will publish its selected drugs on February 1.)

Government 40

Government Marketing Marketing Publishing 40

IP and Legal Filings

AUGUST 18, 2021

In the latest move, the China Intellectual Property Administration and Bank of China have signed a strategic cooperation agreement. Under market economy conditions, innovation cannot continue without IP protection and financial support. Whereas, South Korea also saw a steep rise in filing, with an increase of 9.2%

IP 71

IP Intellectual Property Government Trademark 71

IPilogue

AUGUST 31, 2021

Support the Trade-Related Aspect of Intellectual Property Rights Waiver (TRIPS) to waive IP rights for COVID vaccines and ensure technology transfer between nations. Increasing the ambition of those targets in the 2025-30 period. COVID-Related Trade Policy. Reinstate the tariff on imported PPE. Media Policy .

IP 106

IP Privacy Social Media Intellectual Property 106